Enterprise Value
4.263B
Cash
412.1M
Avg Qtr Burn
-127.2M
Short % of Float
5.89%
Insider Ownership
3.60%
Institutional Own.
88.26%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
DTX301 Details Ornithine transcarbmylase deficiency | Phase 3 Update | |
DTX401 Details Glycogen Storage Disease Type Ia | Phase 3 Update | |
GTX-102 Details Angelman Syndrome | Phase 3 Initiation | |
UX143 (Setrusumab) Details Osteogenesis imperfecta | Phase 2/3 Update | |
UX053 Details Rare diseases, glycogen storage disease type III | Phase 1/2 Data readout | |
UX701 Details Wilson's disease, Rare diseases | Phase 1/2 Data readout | |
UX111 (ABO-102) Details Rare diseases, Sanfilippo Syndrome | Phase 1/2 Update |